StockData

ANI Pharmaceuticals vs Phibro Animal Health

ANIP and PAHC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ANIP and PAHC compare

ANI Pharmaceuticals and Phibro Animal Health are about the same size, with market caps of $1.6B and $1.4B.

On earnings, Phibro Animal Health is cheaper: it trades at 14.4× trailing earnings, against 14.9× for ANI Pharmaceuticals.

ANI Pharmaceuticals grew revenue faster over the last twelve months (30.9% versus 17.1% for Phibro Animal Health).

ANI Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 11.1% compared with 6.6% at Phibro Animal Health.

Phibro Animal Health pays a dividend yielding 1.4%; ANI Pharmaceuticals does not pay one.

Phibro Animal Health scores higher on the StockData Score (22 against 14 for ANI Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricANIPPAHC
Size and price
Market cap$1.6B$1.4B
Share price$69.99$34.92
Change, 1 year−16.7%−22.6%
Change, 5 years71.7%67.2%
Beta (5Y)0.65−0.07
Employees9702,605
StockData Score
Total score1422 (better)
Valuation score55
Growth score26 (better)
Performance score46 (better)
Health score3 (better)2
Dividend score03 (better)
Valuation
P/E14.9×14.4× (better)
P/S1.6×0.9× (better)
P/B2.7× (better)3.7×
EV/EBITDA6.6×5.4× (better)
P/FCF9.3× (better)144×
PEG–0.32
FCF yield10.8% (better)0.70%
Fair value$133.72$65.12
Margin of safety47.7% (better)46.4%
Growth
Revenue growth (TTM)30.9% (better)17.1%
Revenue growth, 5Y average33.5% (better)12.7%
Net income growth (TTM)–107%
EPS growth (TTM)–104%
EPS growth, 5Y average–12.6%
Profitability
Gross margin60.4% (better)33.8%
Operating margin15.4% (better)12.8%
Net margin11.1% (better)6.6%
FCF margin17.7% (better)0.65%
Return on equity21.0%29.7% (better)
Return on invested capital21.3%24.7% (better)
Financial health
Debt / equity0.50–
Net debt / EBITDA−0.25–
Interest coverage4.8× (better)4.2×
Current ratio2.912.96 (better)
Altman Z-score2.533.02 (better)
Piotroski F-score7 (better)6
Dividends and buybacks
Dividend yield–1.4%
Payout ratio0.32%19.5%
Years of dividend growth–0
Dividend growth, 5Y average–0.00%
Buyback yield1.4%–
Shareholder yield1.4% (better)1.4%
Ownership
Held by institutions100%51.8%
Held by insiders12.3%98.9%
Insider net buying, 12 months−$13.6M (better)−$23.0M
Short interest, % of float17.8%233%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.